WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, […]
Revenues were $2.3 billion in the quarterOperating margin was 9.5%Diluted earnings per share was $4.23Backlog of $45.2 billionReiterates long-term financial […]